P-323 RAS mutations in metastatic colorectal cancer in central Tunisia
نویسندگان
چکیده
منابع مشابه
The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
PURPOSE Unlike cetuximab, there is a paucity of biomarkers for bevacizumab as predictors of outcome in metastatic colorectal cancer (mCRC) patients. Obviously exploring the worth of some potential markers in this setting is warranted. The purpose of this study was to investigate the predictive value of the presence of K-RAS and B-RAF mutations on the outcome of patients with mCRC treated with F...
متن کاملK-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients.
K-ras gene mutations have been reported as early events in colorectal tumorigenesis, but their role in tumor initiation and development is still unclear. To analyze and compare K-ras mutational patterns between colorectal tissues at different stages of tumor progression in individual patients, 65 colorectal tissue samples, including carcinoma, adenoma, histologically normal mucosa, submucosal m...
متن کاملPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
BACKGROUND Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouraci...
متن کاملSpectrum of K ras mutations in Pakistani colorectal cancer patients
The incidence of colorectal cancer (CRC) is increasing daily worldwide. Although different aspects of CRC have been studied in other parts of the world, relatively little or almost no information is available in Pakistan about different aspects of this disease at the molecular level. The present study was aimed at determining the frequency and prevalence of K ras gene mutations in Pakistani CRC...
متن کاملK-Ras mutations are changing practice in advanced colorectal cancer.
L ast month, an expert panel said that patients with advanced colorectal cancer should not be treated with cetuximab or panitumumab if their tumors have mutations in the K-Ras oncogene. The major new recommendation from the National Comprehensive Cancer Network (NCCN), based on a consensus of experts at 21 comprehensive cancer centers across the United States, reflects a change in practice that...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2020
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2020.04.405